高级检索
当前位置: 首页 > 详情页

Fertility preservation in males with cancer of trends, region development, and efficacy in mainland China from 16 regions Chinese sperm banks

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

机构: [1]Sichuan Univ, West China Univ Hosp 2, Dept Androl, Sichuan Human Sperm Bank, Chengdu, Peoples R China [2]Guangdong Prov Fertil Hosp, Sci Inst, NHC Key Lab Male Reprod & Genet Guangdong Prov Rep, Guangzhou 510062, Guangdong, Peoples R China [3]Zhejiang Mater Child & Reprod Hlth Ctr, Hangzhou 310000, Zhejiang, Peoples R China [4]Natl Res Inst Family Planning, Human Sperm Bank, Beijing 100098, Peoples R China [5]Guangxi Med Univ, Affiliated Hosp 1, Guilin 530021, Guangxi, Peoples R China [6]Huazhong Univ Sci & Technol, Tongji Med Coll, Ctr Reprod Med, Hubei Prov Human Sperm Bank, Wuhan 430010, Hubei, Peoples R China [7]Zhengzhou Univ, Affiliated Hosp 3, Henan Human Sperm Bank, Zhengzhou 450014, Henan, Peoples R China [8]Kunming Med Univ, Affiliated Hosp 1, Dept Urol Surg, Kunming 650032, Yunnan, Peoples R China [9]Reprod & Genet Hosp CITIC Xiangya, Changsha 410008, Hunan, Peoples R China [10]Chongqing Res Inst Populat & Family Planning Sci &, Human Sperm Bank, Chongqing 401121, Peoples R China [11]Northwest Womens & Childrens Hosp, Xian 610045, Shaanxi, Peoples R China [12]Nanchang Reprod Hosp, Nanchang 330001, Jiangxi, Peoples R China [13]Lanzhou Univ, Hosp 1, Human Sperm Bank, Lanzhou 730099, Gansu, Peoples R China [14]First Hosp Jilin Univ, Changchun 130021, Jilin, Peoples R China [15]Anhui Med Univ, Affiliated Hosp 1, Anhui Prov Human Sperm Bank, Hefei 230022, Anhui, Peoples R China [16]Shanxi Bethune Hosp, Shanxi Acad Med Sci, Sperm Bank, Taiyuan 030001, Shanxi, Peoples R China [17]Sichuan Univ, Key Lab Birth Defects & Related Dis Women & Childr, Minist Educ, Chengdu, Peoples R China
出处:
ISSN:

关键词: Male cancer Fertility preservation Semen quality Sperm cryopreservation

摘要:
PurposeMale cancer survivors experience confusion about fertility following cancer treatment. The aims of this study were to evaluate survivors' semen quality in different tumor type groups in China and to analyze the current situation and challenges of male cancer patients with sperm cryopreservation.MethodsThis was a multicenter retrospective study of male patients with cancer who underwent sperm cryopreservation in 16 regions of the national sperm banks over an 11-year period from 2010 to 2020.ResultsThe number of male cancer patients with sperm cryopreservation showed an overall upward trend. The development of male cancer fertility preservation (FP) in the eastern, central, and western regions of Chinese displayed imbalance. There are seven tumor types for sperm preservation in the top incidence ten tumor types, including lymphoma, leukemia, nasopharyngeal carcinoma, sarcoma, thyroid cancer, and brain tumor. Moreover, nasopharyngeal carcinoma is a high incidence rate in China, which is related to high sperm preservation rate, different from other countries. The most percentage of males receiving sperm cryopreservation in the testicular cancers (15-39 years old) of China in 2020 was 5.55%, 1.29% in the lymphoma, and 0.39% in the leukemia. According to the type of cancer, a statistically significant lower pre-sperm density, total sperm output, and post-sperm density was observed in testicular cancers. It is worth noting that the prevalence of azoospermia 22.2% in leukemia patients attribute to urgent treatment before sperm cryopreservation. Disposition of cryopreserved sperm categories included continued storage (47.2%), discarded (9%), death (0.9%), and use (3.7%).ConclusionThis study provides the first comprehensive national statistical census and review of fertility preservation in male cancer patients with respect to trends, prevalence, and cancer types. The development of male cancer fertility preservation in China is imbalanced and percentage of males receiving sperm cryopreservation in the adolescent and young adult cancers was low. Sixteen human sperm banks from China analyze current problems and challenges, and then prioritize steps toward the achievement of the FP strategy framework for Healthy China 2030.

基金:
语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2023]版:
大类 | 3 区 医学
小类 | 3 区 遗传学 3 区 妇产科学 3 区 生殖生物学
最新[2023]版:
大类 | 3 区 医学
小类 | 3 区 遗传学 3 区 妇产科学 3 区 生殖生物学
JCR分区:
出版当年[2023]版:
Q1 OBSTETRICS & GYNECOLOGY Q2 GENETICS & HEREDITY Q2 REPRODUCTIVE BIOLOGY
最新[2023]版:
Q1 OBSTETRICS & GYNECOLOGY Q2 GENETICS & HEREDITY Q2 REPRODUCTIVE BIOLOGY

影响因子: 最新[2023版] 最新五年平均 出版当年[2023版] 出版当年五年平均 出版前一年[2023版]

第一作者:
第一作者机构: [1]Sichuan Univ, West China Univ Hosp 2, Dept Androl, Sichuan Human Sperm Bank, Chengdu, Peoples R China [17]Sichuan Univ, Key Lab Birth Defects & Related Dis Women & Childr, Minist Educ, Chengdu, Peoples R China
共同第一作者:
通讯作者:
通讯机构: [1]Sichuan Univ, West China Univ Hosp 2, Dept Androl, Sichuan Human Sperm Bank, Chengdu, Peoples R China [17]Sichuan Univ, Key Lab Birth Defects & Related Dis Women & Childr, Minist Educ, Chengdu, Peoples R China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:43378 今日访问量:0 总访问量:3120 更新日期:2024-09-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持:重庆聚合科技有限公司 地址:成都市人民南路四段55号